Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics Plc ADR (NQ: AUTL )

2.900 -0.230 (-7.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Autolus Therapeutics Plc ADR

Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
- Expanding the Autolus toolkit of T-cell engineering modules against complex and immunologically hostile cancers, including solid cancer applications 
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Host Virtual Capital Markets Day
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Publication in Molecular Therapy
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces resignation of Chief Financial Officer
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces Board changes
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Announces Pricing of Public Offering
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Announces Proposed Public Offering in the United States
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022
From Autolus Therapeutics plc
Via GlobeNewswire
Moderna exercises option to license proprietary targeting technology from Autolus
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
From Autolus Therapeutics plc
Via GlobeNewswire
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.